Hanmi Group to Boost Cash Dividends, Targets Higher Shareholder Returns

Hanmi Group says it will push ahead with a larger cash-dividend policy to boost shareholder value. In a statement on October 16, 2025, the group said Hanmi Science aims for a total shareholder return of at least 30%, Hanmi Pharmaceuticals 20%, and JVM 20% or more, in line with the shareholder-return policy it announced at last year’s investor day.

The plan includes specific cash dividends per share: 300 won for Hanmi Science ordinary shares, 2,000 won for Hanmi Pharmaceuticals ordinary shares, and 650 won for JVM ordinary shares. At current market prices, the corresponding dividend yields are around 0.79% for Hanmi Science, 0.40% for Hanmi Pharmaceuticals, and 2.5% for JVM.

The proposed dividends will be submitted for final approval at each company’s regular shareholders’ meeting on October 31. If approved, the distributions would be implemented in line with the groups’ stated return targets.

Kim Jae-gyo, chief executive of Hanmi Science, said the group intends to maximize future business opportunities and strategic growth to raise overall corporate value. He emphasized balancing growth investments with shareholder-friendly policies and maintaining a stable financial structure to support both aims.

The move is framed as a continuation of the group’s commitment to shareholder returns that began with last year’s Hanmi Vision Day, a corporate investor relations event where the policy was officially announced.

This development matters beyond Korea for U.S. readers because it signals how major Korean pharmaceutical groups are managing capital and returning cash to investors. Stronger or more predictable dividends can influence stock valuations, attract foreign investment, and shape collaboration dynamics with U.S. firms in licensing, partnerships, or supply chains.

For context, Hanmi Group comprises Hanmi Science, Hanmi Pharmaceuticals, and JVM, collectively positioned as part of Korea’s mid- to large-cap biotech and pharmaceutical sector. The announcements reflect ongoing governance and capital-allocation choices that can affect market sentiment and cross-border investment in Asia’s biopharma market.